JP Morgan commented on Thermo Fisher Scientific TMO in a report released today. In the report, JP Morgan was positive in its assessment of the company.
JP Morgan writes, "In an effort to better understand the market opportunity for Phadia, Thermo's recent
$3.5B acquisition (announced on 5/19), we surveyed 26 U.S. allergists and
immunologists familiar with the allergen-specific serum IgE test, known as
ImmunoCAP (~85% of Phadia revenues). Although we remain somewhat concerned
about ROIC on the deal, despite management commentary that it was above the 10%
internal hurdle rate, we came away believing that Phadia should provide growth above
TMO's current levels (at least in U.S.), and given a renewed focus on capital
deployment, and what we view as additional room for upside to both the multiple and
EPS, we maintain our Overweight rating on TMO shares. "
JP Morgan currently has an Overweight rating on Thermo Fisher Scientific and a price target of $72. Shares of Thermo Fisher Scientific closed at $62.80 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in